PASI 100 at Week 127

Male | 40 years | SILIQ Q2W

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 64%

 

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 49 years | SILIQ Q2W

Psoriasis patient photos: 28% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 28%

 

Psoriasis patient photos: 28% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 56 years | SILIQ Q2W

Psoriasis patient photos: 30% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 30%

 

Psoriasis patient photos: 30% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 50 years | SILIQ Q2W

Psoriasis patient photos: 15% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 15%

 

Psoriasis patient photos: 15% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 27 years | SILIQ Q2W

Psoriasis patient photos: 92% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 92%

 

Psoriasis patient photos: 92% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 27 years | SILIQ Q2W

Psoriasis patient photos: 92% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 92%

 

Psoriasis patient photos: 92% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 40 years | SILIQ Q2W

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 64%

 

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 40 years | SILIQ Q2W

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 64%

 

Psoriasis patient photos: 64% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 34 years | SILIQ Q2W

Psoriasis patient photos: 53% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 53%

 

Psoriasis patient photos: 53% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 34 years | SILIQ Q2W

PPsoriasis patient photos: 53% BSA before vs 0% BSA at 12 weeks with SILIQ
Before

BSA 53%

 

Psoriasis patient photos: 53% BSA before vs 0% BSA at 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

Male | 34 years | SILIQ Q2W

Psoriasis patient photos: 53% BSA before vs 0% BSA after 12 weeks with SILIQ
Before

BSA 53%

 

Psoriasis patient photos: 53% BSA before vs 0% BSA after 12 weeks with SILIQ
Week 12

BSA 0% |PASI Response 100

These photos are of actual patients treated with SILIQ in medical studies. Photos have not been retouched. Individual results may vary.

PASI 100 at Week 527

Male | 39 years | SILIQ Q2W

Psoriasis patient photos: 56% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 56%

 

Psoriasis patient photos: 56% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 39 years | SILIQ Q2W

Psoriasis patient photos: 56% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 56%

 

Psoriasis patient photos: 56% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 58 years | SILIQ Q2W

Psoriasis patient photos: 16.5% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 16.5%

 

Psoriasis patient photos: 16.5% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 59 years | SILIQ Q2W

Psoriasis patient photos: 50% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 50%

 

Psoriasis patient photos: 50% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 59 years | SILIQ Q2W

Psoriasis patient photos: 50% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 50%

 

Psoriasis patient photos: 50% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Female | 36 years | SILIQ Q2W

Psoriasis patient photos: 20% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 23%

 

Psoriasis patient photos: 20% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% | PASI Response 100

Female | 36 years | SILIQ Q2W

Psoriasis patient photos: 23% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 23%

 

Psoriasis patient photos: 23% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 39 years | SILIQ Q2W

Psoriasis patient photos: 39% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 39%

 

Psoriasis patient photos: 39% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

Male | 34 years | SILIQ Q2W

Psoriasis patient photos: 20% BSA before vs 0% BSA after 52 weeks with SILIQ
Before

BSA 20%

 

Psoriasis patient photos: 20% BSA before vs 0% BSA after 52 weeks with SILIQ
Week 52

BSA 0% |PASI Response 100

These photos are of actual patients treated with SILIQ in medical studies. Photos have not been retouched. Individual results may vary.

Real Patient Experience With SILIQ

Male | 51 years | SILIQ Q2W

Psoriasis patient photos: 28% BSA before vs 0% BSA after 3 months with SILIQ
Start of treatment

BSA 80%

 

Psoriasis patient photos: 28% BSA before vs 0% BSA after 3 months with SILIQ
By week 12

BSA 0% | PASI Response 100

Male | 51 years | SILIQ Q2W

Psoriasis patient photos: 80% BSA before vs 0% BSA after 3 months with SILIQ
Start of treatment

BSA 80%

 

Psoriasis patient photos: 80% BSA before vs 0% BSA after 3 months with SILIQ
By week 12

BSA 0% | PASI Response 100

These photos are of actual patients treated with SILIQ. Photos have not been retouched. Individual results may vary.

BSA, Body Surface Area; PASI, Psoriasis Area and Severity index; Q2W, once every 2 weeks.

Share their
 success stories

Watch stories from real patients who spent years stuck in the loop of
 failures with other plaque psoriasis medications before finding relief with SILIQ. Individuals results may vary.

Rosi knows what it’s
 like to feel like nothing
 will ever work.

video-img play-button-icon play-button

Elizabeth tried many
 biologics without
  lasting success.

video-img play button play button

Get SILIQ certified

It’s simple. Enrolling through the REMS portal takes just a few minutes.

Enroll now
close button
 
 
 
 
 
 
 
 
 
close button
 
 
 
 
 
 
 
 
 

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Contraindications Do not use SILIQ in patients with Crohn's disease because SILIQ may cause worsening of disease; or in patients with clinically significant hypersensitivity to brodalumab or to any of the excipients in SILIQ or components of the container.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com or by calling the SILIQ REMS Program Call Center at 855-511-6135855-511-6135.

Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis requiring hospitalization, have been reported. If a serious hypersensitivity reaction occurs, immediately discontinue SILIQ and initiate appropriate therapy.

Infections SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection.

Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur.

Risk for Latent Tuberculosis (TB) Reactivation Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Eczematous Eruptions Postmarketing cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, have been reported. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of SILIQ. Some cases of severe eczematous eruptions resulted in hospitalization. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing SILIQ.

Crohn’s Disease In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease. Discontinue SILIQ if a patient develops Crohn’s disease.

Immunizations Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/medwatch.

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.

Expand plus Close close
Indication and Important Safety Information
Indication and Important Safety Information

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to ...

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR

Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or ...

WARNING: SUICIDAL IDEATION AND BEHAVIOR

Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or ...

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL IDEATION AND BEHAVIOR
Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Prior to prescribing SILIQ, weigh the potential risks and benefits in patients with a history of depression and/or suicidal ideation or behavior. Patients with new or worsening suicidal ideation and behavior should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes [see Warnings and Precautions (5.1) in the full Prescribing Information].

Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2) in the full Prescribing Information].

Contraindications Do not use SILIQ in patients with Crohn's disease because SILIQ may cause worsening of disease; or in patients with clinically significant hypersensitivity to brodalumab or to any of the excipients in SILIQ or components of the container.

SILIQ Risk Evaluation and Mitigation Strategy (REMS) Program SILIQ is available only through a restricted program called the SILIQ REMS because of observed suicidal ideation and behavior in patients treated with SILIQ. Before prescribing SILIQ, prescribers must be certified with the program, have each patient sign a Patient-Prescriber Agreement Form, and provide the patient a Wallet Card describing symptoms requiring immediate medical evaluation. Pharmacies must be certified and only dispense to patients authorized to receive SILIQ. More information is available at SILIQREMS.com or by calling the SILIQ REMS Program Call Center at 855-511-6135855-511-6135.

Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis requiring hospitalization, have been reported. If a serious hypersensitivity reaction occurs, immediately discontinue SILIQ and initiate appropriate therapy.

Infections SILIQ may increase the risk of infections. Serious infections and fungal infections were observed at a higher rate in patients treated with SILIQ than placebo-treated patients in clinical trials, including one case of cryptococcal meningitis that led to discontinuation of therapy.

Consider risks and benefits prior to prescribing SILIQ in patients with a chronic infection or history of recurrent infection.

Instruct patients to seek treatment if signs or symptoms of a chronic or acute infection occur.

Risk for Latent Tuberculosis (TB) Reactivation Evaluate patients for TB prior to initiating treatment with SILIQ and do not treat patients with active TB. Initiate treatment for latent TB prior to starting SILIQ and consider anti-TB therapy prior to initiation in patients with history of latent TB if adequate treatment cannot be confirmed. Monitor closely for symptoms of active TB during and after treatment.

Eczematous Eruptions Postmarketing cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, have been reported. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of SILIQ. Some cases of severe eczematous eruptions resulted in hospitalization. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing SILIQ.

Crohn’s Disease In clinical trials, which excluded Crohn’s patients, one SILIQ patient was withdrawn after developing Crohn’s disease. Discontinue SILIQ if a patient develops Crohn’s disease.

Immunizations Avoid use of live vaccines in patients treated with SILIQ.

Adverse Reactions The most commonly reported adverse reactions in clinical trials were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or the FDA at 1-800-FDA-1088, or visit www.fda.gov/medwatch.

INDICATION

SILIQ® injection is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Click here for full Prescribing Information, including Boxed Warning about suicidal ideation and behavior.

stye